Appclon Acquires Patent Rights for CAR-T Cell Therapy
[Asia Economy Reporter Minji Lee] Appclone announced on the 15th that it has obtained a patent for an antibody specifically recognizing malignant B cells (blood cancer), or its antigen-binding fragment, including a chimeric antigen receptor containing them.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- US Demands Transfer of 400kg Enriched Uranium... Iran Insists on Recognition of Hormuz Rights
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The company stated, "We plan to develop a treatment that overcomes the problems of existing allogeneic therapeutics using one of our platforms, the zCAR-T platform."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
